Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rotavirus Vaccine Injury Compensation Bill Likely To Wait Until 2001

Executive Summary

Legislation to extend Vaccine Injury Compensation Program coverage to rotavirus vaccine-related intussusception surgery will probably wait until 2001, HHS Division of Vaccine Injury Compensation Director Thomas Balbier told an Advisory Commission on Childhood Vaccines meeting Sept. 6.

You may also be interested in...



Vaccine Injury Compensation May Cut Surgery Requirement For Rotashield

HHS is considering a proposal that would broaden Vaccine Injury Compensation Program coverage of intussusception cases associated with use of Wyeth-Ayerst's rotavirus vaccine Rotashield.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Latest Headlines
See All
UsernamePublicRestriction

Register

PS036641

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel